Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
Kacper Odziomek, Member of the Student Council at the Polish Space Agency SA, shared a proud post on LinkedIn:
“I am pleased to share that I have earned certificates of achievement in two Pharmacology courses from Harvard Medical School Professional, Corporate, and Continuing Education.
The Clinical Drug Development course explored the full process of bringing new therapeutics from concept to patient, with emphasis on trial design, modern adaptive methodologies, bias and confounding control, data analysis, and the ethical and regulatory frameworks that ensure patient safety.
The Drug Delivery course examined the science and engineering behind optimizing therapeutic delivery, including systemic vs. local administration, overcoming biological barriers, polymeric and nanoparticle carriers, triggerable release systems, and emerging innovations such as closed-loop delivery technologies.
The participation was financed by the Ministry of Science and Higher Education within the project “Support for students in improving their competencies and skills” carried out under the European Funds for Social Development 2021-2027 Programme (FERS.01.05-IP.08-004/23).”
Congratulations to Kacper Odziomek on this outstanding achievement!
More winner stories featured in Hemostasis Today.
-
Aug 15, 2025, 23:36Irene M Lang's Editorial on Getting Risk Assessment Right in Acute Pulmonary Embolism
-
Aug 15, 2025, 23:31Richard Buka: Many Improvements Needed in HIT Management
-
Aug 14, 2025, 23:47World Thrombosis Day: Know your Risk in DVT
-
Aug 14, 2025, 12:52JAMA Review: Immune Thrombotic Thrombocytopenic Purpura (iTTP)
-
Aug 14, 2025, 12:33Louise Bannon: The World Thrombosis Day Campaign is Calling on Industry Leaders
-
Aug 15, 2025, 23:35SEC61B Mediated Platelet Hyperactivity in People with Diabetes
-
Aug 15, 2025, 23:32Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery
-
Aug 15, 2025, 23:31Marc Carrier: Low Awareness of Cancer-Associated Thrombosis Among Canadians
-
Aug 14, 2025, 23:47Health-related Quality of Life in Children with von Willebrand Disease
-
Aug 14, 2025, 17:54Omid Seidizadeh: From Genotype and Phenotype! Variability in Type 2 von Willebrand Disease
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact